|
News
News Releases
| July 10, 2008 |
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib
in a
Combination Regimen for Patients with Relapsed Multiple Myeloma |
| May 15, 2008 |
Proteolix Appoints Thomas Kassberg Executive Vice President of Corporate Development |
| May 1, 2008 |
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with
Relapsed Solid Tumors |
April 2, 2008 |
Proteolix’s Carfilzomib Receives Orphan Drug Designation
for Treatment of Multiple Myeloma |
February 25, 2008 |
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer |
| December 6, 2007 |
Proteolix Announces Clinical Results with Carfilzomib
to be Reported at ASH 2007 Annual Meeting |
| October 10, 2007 |
Proteolix Initiates Multicenter Open-label Study of the Safety and
Activity of Carfilzomib in Subjects with Relapsed Solid Tumors |
| August 15, 2007 |
The Multiple Myeloma Research Consortium (MMRC) and Proteolix initiate Phase 2 clinical trial investigating Carfilzomib for the treatment of Multiple Myeloma |
| May 24, 2007 |
Interim Clinical Results on Carfilzomib to be Presented at ASCO 2007 |
| April 26, 2007 |
Proteolix Hires Dr. Lori Kunkel as Chief Medical Officer |
| January 16, 2007 |
Proteolix Elects Dr. Michael Kauffman Chairman of the Board -
Brings Extensive Drug Discovery and Clinical Development Experience |
| May 31, 2006 |
Proteolix Announces Closing of $45 million Series B Financing. Funding To Be
Used to Expand Clinical Trials. |
Publications
| 2007 |
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007 Jul 1;67(13):6383-91. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK |
| 2007 |
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood. 2007 Jun 25. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. |
Recent & Upcoming Presentations
|
|
News
